Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848182 · ClinicalTrials.gov registry record · Phase 2
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03848182 is a Phase 2 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT03848182, a Phase 2 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy. In mice with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that patients receive from childhood) combined with Gemcitabine activates these killer T cells. (Gemcitabine improves T cell responses) These killer T cells are able to destroy tumor cells uploaded with TT protein (such studies are planned in future clinical trials). The goal of this study is to test whether one TT vaccination combined with Gemcitabine treatment activates the same T cells in pancreatic cancer patients.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL TT vaccine booster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2019-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03848182
The ClinicalTrials.gov registry entry for NCT03848182 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT03848182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03848182 about?
NCT03848182 is a clinical study titled "Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer". The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy. In mice with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that patients receive from childhoo...
What is the current status of trial NCT03848182?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-07-21. Estimated completion is 2019-11-11.
What interventions are being tested in trial NCT03848182?
The interventions under investigation include: Gemcitabine (DRUG), TT vaccine booster (BIOLOGICAL).
Who is sponsoring clinical trial NCT03848182?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.